Bavarian Nordic A/S (BVNKF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Bavarian Nordic A/S (BVNKF) with AI Score 52/100 (Hold). Bavarian Nordic A/S is a biotechnology company specializing in the development, manufacturing, and commercialization of life-saving vaccines. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 15, 2026Bavarian Nordic A/S (BVNKF) Healthcare & Pipeline Overview
Bavarian Nordic A/S is a vaccine developer focused on infectious diseases, with a portfolio including approved vaccines for smallpox, monkeypox, rabies, tick-borne encephalitis, and Ebola. The company leverages its MVA-BN technology platform to develop and commercialize vaccines, positioning it as a key player in the global vaccine market.
Investment Thesis
Bavarian Nordic presents a compelling investment case driven by its established portfolio of approved vaccines and promising pipeline of vaccine candidates. The company's revenue is supported by ongoing demand for its smallpox and monkeypox vaccines, particularly in response to global health concerns. The Phase III clinical trials for MVA-BN RSV represent a significant growth catalyst, targeting a large market with substantial unmet needs. With a P/E ratio of 10.33 and a profit margin of 22.2%, Bavarian Nordic demonstrates financial stability and profitability. However, potential risks include clinical trial failures, competition from other vaccine manufacturers, and reliance on government contracts.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $2.20 billion reflects investor confidence in Bavarian Nordic's vaccine portfolio and growth prospects.
- P/E ratio of 10.33 indicates a potentially undervalued stock compared to its peers in the biotechnology industry.
- Profit margin of 22.2% demonstrates efficient operations and strong profitability.
- Gross margin of 48.5% highlights the company's ability to generate substantial revenue from its vaccine sales.
- Beta of 1.09 suggests that the stock's volatility is similar to the overall market.
Competitors & Peers
Strengths
- Established portfolio of approved vaccines.
- Proprietary MVA-BN technology platform.
- Strong relationships with governments and international organizations.
- Experienced management team.
Weaknesses
- Reliance on government contracts.
- Competition from larger pharmaceutical companies.
- Potential for clinical trial failures.
- Limited product diversification.
Catalysts
- Upcoming: Phase III clinical trial results for MVA-BN RSV vaccine.
- Upcoming: Regulatory approval decisions for vaccine candidates.
- Ongoing: Government contracts and procurement agreements for existing vaccines.
- Ongoing: Expansion into new geographic markets.
- Ongoing: Strategic partnerships and collaborations.
Risks
- Potential: Clinical trial failures and regulatory setbacks.
- Potential: Competition from larger pharmaceutical companies.
- Potential: Patent expirations and generic competition.
- Ongoing: Reliance on government contracts and funding.
- Ongoing: Public skepticism towards vaccines.
Growth Opportunities
- MVA-BN RSV Vaccine: Bavarian Nordic's MVA-BN RSV vaccine, currently in Phase III clinical trials, targets the respiratory syncytial virus, a significant cause of respiratory illness in infants and older adults. The RSV vaccine market is projected to reach billions of dollars in the coming years, presenting a substantial growth opportunity for Bavarian Nordic. Successful completion of clinical trials and regulatory approval could drive significant revenue growth.
- ABNCoV2 Vaccine: The ABNCoV2 vaccine candidate, which has completed Phase II clinical trials for the treatment of SARS-CoV-2, represents another growth opportunity for Bavarian Nordic. While the initial surge in demand for COVID-19 vaccines has subsided, there remains a need for booster shots and variant-specific vaccines. Bavarian Nordic's ABNCoV2 vaccine could capture a share of this market.
- TAEK-VAC Cancer Vaccine: Bavarian Nordic is developing TAEK-VAC, a cancer vaccine targeting advanced HER2 and brachyury-expressing cancers. This vaccine is currently in Phase I/II clinical trials. The cancer vaccine market is a rapidly growing area, driven by advances in immunotherapy and personalized medicine. Successful development and commercialization of TAEK-VAC could provide a significant long-term growth driver for Bavarian Nordic.
- Geographic Expansion: Bavarian Nordic has the opportunity to expand its geographic presence and increase sales in emerging markets. Many developing countries have a high burden of infectious diseases and a need for affordable vaccines. By partnering with local distributors and participating in global health initiatives, Bavarian Nordic can tap into these markets and drive revenue growth.
- Strategic Partnerships: Bavarian Nordic can pursue strategic partnerships and collaborations to expand its product portfolio and accelerate its research and development efforts. The company already has license and collaboration agreements with AdaptVac, National Cancer Institute, and Public Health Service. Additional partnerships with other biotechnology companies, research institutions, and government agencies could provide access to new technologies, funding, and expertise.
Opportunities
- Expansion into emerging markets.
- Development of new vaccines for unmet medical needs.
- Strategic partnerships and collaborations.
- Increased demand for vaccines due to global health threats.
Threats
- Regulatory changes and challenges.
- Patent expirations and generic competition.
- Economic downturns and reduced government spending.
- Public skepticism towards vaccines.
Competitive Advantages
- Proprietary MVA-BN technology platform for vaccine development.
- Established manufacturing capabilities for vaccine production.
- Regulatory approvals and market access for key vaccines.
- Strong relationships with governments and international organizations.
About BVNKF
Bavarian Nordic A/S, founded in 1992 and headquartered in Hellerup, Denmark, is a biotechnology company dedicated to developing, manufacturing, and commercializing life-saving vaccines. The company's core business revolves around its portfolio of vaccines targeting infectious diseases. Bavarian Nordic's flagship products include the non-replicating smallpox and monkeypox vaccines, marketed under the names IMVAMUNE, IMVANEX, and JYNNEOS. These vaccines have gained prominence due to their role in global health security. In addition to its smallpox and monkeypox vaccines, Bavarian Nordic offers a rabies vaccine for human use under the Rabipur/RabAvert brand and a tick-borne encephalitis vaccine under the Encepur brand. The company also provides an Ebola vaccine under the MVABEA name. Bavarian Nordic is actively engaged in research and development, with several vaccine candidates in various stages of clinical trials. These include MVA-BN (freeze-dried) for smallpox, MVA-BN RSV for respiratory syncytial virus, ABNCoV2 for SARS-CoV-2, and TAEK-VAC for advanced HER2 and brachyury-expressing cancers. Bavarian Nordic operates globally, with a presence in the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, and Japan.
What They Do
- Develops non-replicating smallpox and monkeypox vaccines.
- Manufactures and commercializes rabies vaccines for human use.
- Offers tick-borne encephalitis vaccines.
- Provides Ebola vaccines.
- Develops vaccines for respiratory syncytial virus (RSV).
- Develops vaccines for SARS-CoV-2.
- Develops cancer vaccines targeting HER2 and brachyury-expressing cancers.
Business Model
- Develops and manufactures vaccines for infectious diseases.
- Commercializes vaccines through direct sales and distribution agreements.
- Partners with governments and international organizations to supply vaccines.
- Generates revenue from vaccine sales, licensing agreements, and research grants.
Industry Context
The biotechnology industry is characterized by intense research and development, high regulatory hurdles, and significant growth potential. The global vaccine market is driven by increasing awareness of infectious diseases and government initiatives to promote vaccination. Bavarian Nordic competes with other vaccine manufacturers, including BRCTF (BriaCell Therapeutics Corp), GLPGF (Galapagos NV), HAWPY (Haw Par Corp Ltd), HBMHF (HBM Healthcare Investments AG), and HYPMY (Hypera S.A.). Bavarian Nordic's focus on specialized vaccines and its established manufacturing capabilities provide a competitive edge in this dynamic market.
Key Customers
- Governments and public health agencies.
- Hospitals and clinics.
- Travelers and individuals seeking protection against infectious diseases.
- Military and defense organizations.
Financials
Chart & Info
Bavarian Nordic A/S (BVNKF) stock price: Price data unavailable
Latest News
-
Bavarian Nordic A/S – Notice Convening Annual General Meeting
globenewswire.com · Mar 24, 2026
-
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
Yahoo! Finance: BVNKF News · Mar 23, 2026
-
Mpox Is on the Rise in the U.S. 3 Vaccine Stocks Worth a Second Look.
Yahoo! Finance: BVNKF News · Mar 17, 2026
-
Is Bavarian Nordic (CPSE:BAVA) Pricing Reflect Its Vaccine Role And DCF Earnings Signals?
Yahoo! Finance: BVNKF News · Mar 15, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BVNKF.
Price Targets
Wall Street price target analysis for BVNKF.
MoonshotScore
What does this score mean?
The MoonshotScore rates BVNKF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Bavarian Nordic A/S – Notice Convening Annual General Meeting
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
Mpox Is on the Rise in the U.S. 3 Vaccine Stocks Worth a Second Look.
Is Bavarian Nordic (CPSE:BAVA) Pricing Reflect Its Vaccine Role And DCF Earnings Signals?
Leadership: Paul John Chaplin
CEO
Paul Chaplin serves as the CEO of Bavarian Nordic A/S. His background includes extensive experience in the pharmaceutical and biotechnology industries. He has held various leadership positions in research and development, commercial operations, and strategic planning. His expertise spans vaccine development, manufacturing, and global market access. Chaplin's academic credentials include advanced degrees in relevant scientific disciplines, complemented by business management training.
Track Record: Under Paul Chaplin's leadership, Bavarian Nordic has achieved significant milestones, including the expansion of its vaccine portfolio, the successful completion of clinical trials, and the securing of key government contracts. He has overseen the company's response to global health emergencies, such as the monkeypox outbreak, and has driven the development of innovative vaccine candidates. His strategic decisions have positioned Bavarian Nordic as a key player in the global vaccine market.
BVNKF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Bavarian Nordic A/S (BVNKF) may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks involves higher risks due to the potential for less transparency and greater price volatility.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Potential for lower trading volume and liquidity.
- Greater price volatility and wider bid-ask spreads.
- Higher risk of fraud or manipulation.
- Limited regulatory oversight and investor protection.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Review any available analyst reports or independent research.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Established history of vaccine development and manufacturing.
- Partnerships with reputable organizations and government agencies.
- Positive clinical trial results for vaccine candidates.
- Experienced management team with relevant industry expertise.
What Investors Ask About Bavarian Nordic A/S (BVNKF)
What does Bavarian Nordic A/S do?
Bavarian Nordic A/S is a biotechnology company focused on developing, manufacturing, and commercializing life-saving vaccines. The company's core business revolves around its portfolio of vaccines targeting infectious diseases, including smallpox, monkeypox, rabies, tick-borne encephalitis, and Ebola. Bavarian Nordic leverages its proprietary MVA-BN technology platform to develop innovative vaccine candidates and collaborates with governments, international organizations, and other biotechnology companies to expand its reach and impact on global health.
What do analysts say about BVNKF stock?
Analyst coverage of BVNKF stock is limited due to its OTC listing. However, the company's financial performance, vaccine pipeline, and market position are key factors considered in valuation assessments. The potential for revenue growth from existing vaccines and new product launches is a positive factor. Investors should conduct their own due diligence and consider the risks associated with investing in OTC stocks before making any investment decisions. Analyst consensus is Unknown.
What are the main risks for BVNKF?
The main risks for BVNKF include clinical trial failures, regulatory setbacks, competition from larger pharmaceutical companies, reliance on government contracts, and public skepticism towards vaccines. Clinical trial failures can significantly impact the company's pipeline and future revenue potential. Regulatory setbacks can delay or prevent the approval of new vaccines. Competition from larger pharmaceutical companies with greater resources and market access can erode market share. Reliance on government contracts makes the company vulnerable to changes in government spending and priorities. Public skepticism towards vaccines can reduce demand and impact sales.
What are the key factors to evaluate for BVNKF?
Bavarian Nordic A/S (BVNKF) currently holds an AI score of 52/100, indicating moderate score. Key strength: Established portfolio of approved vaccines.. Primary risk to monitor: Potential: Clinical trial failures and regulatory setbacks.. This is not financial advice.
How frequently does BVNKF data refresh on this page?
BVNKF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven BVNKF's recent stock price performance?
Recent price movement in Bavarian Nordic A/S (BVNKF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Established portfolio of approved vaccines.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider BVNKF overvalued or undervalued right now?
Determining whether Bavarian Nordic A/S (BVNKF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying BVNKF?
Before investing in Bavarian Nordic A/S (BVNKF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited analyst coverage due to OTC listing.
- Disclosure status on OTC markets is unknown.